Treatment Information for Patients Who Underwent Second 18F-FGln Dynamic PET Scan
| Patient no. | Cancer | Therapy | Time between first and second scans (d) | Dosing |
| 1 | Renal cell carcinoma | CB-839 | 55 | 400 mg 3 times daily |
| 2 | Non–small cell lung cancer | CB-839 | 27 | 400 mg 3 times daily |
| 3 | Glioblastoma multiforme | Nivolumab + radiotherapy | 92 | 200 mg 1 time daily |
| 4 | Glioblastoma multiforme | Pembrolizumab | 68 | 200 mg 1 time daily |
| 5 | Glioblastoma multiforme | TAK-228 | 49 | 3 mg 1 time daily* |
↵* Patient self-discontinued trial after 1 mo.
FOV = field of view for dynamic PET scan.